Stanford University
Showing 41-50 of 2,382 Results
-
Alawab Aldulimy
Contingent Employee, CV Med - Clinical Trials
Current Role at StanfordClinical Researcher
Clinical Research Coordinator -
William Alegria
Lecturer, Medicine - Med/Infectious Diseases
BioDr. Alegria is a board-certified Infectious Diseases Pharmacotherapy specialist and antimicrobial stewardship consultant with the Stanford Antimicrobial Safety and Sustainability Program. He primarily practices in the inpatient setting and is dedicated to developing targeted stewardship interventions in immunocompromised patient populations. His clinical interests include management of infections in immunocompromised hosts, antifungal pharmacotherapy, and difficult-to-treat infections.
Publications (selected)
Navigating recurrent Clostridioides difficile infection without Bezlotoxumab: potential challenges ahead. Arya R, Zimmet AN, Holubar M, Alegria W. Antimicrob Steward Healthc Epidemiol. 2025
How to leverage medication use evaluations for antimicrobial stewardship goals: a primer for physicians. Prasad R, Arya R, Meng L, Holubar M, Alegria W, Zimmet AN.
Antimicrob Steward Healthc Epidemiol. 2025
Beyond the basics: rethinking antimicrobial stewardship by targeting cytomegalovirus immune globulin for immunocompromised patients. Prasad R, Lu B, Veloria D, Mui E, Nelson J, Dhillon G, Deresinski S, Holubar M, Alegria W. Antimicrob Steward Healthc Epidemiol. 2025
No "One-Size-Fits All": chronic "Carryover" diagnoses dilute antibiotic prescribing rates for sinusitis among adults in primary and urgent care settings. Smith M, Hawkins M, Laikijrung C, Mui E, Alegria W, Leung T, Zimmet A, Ha D, Holubar M. Infect Control Hosp Epidemiol. 2024
Combination Antifungal Therapy for Invasive Mucormycosis in Immunocompromised Hosts: A Single-Center Experience. Lu B, Ha D, Shen S, Ferguson Toll J, Kim A, Kim S, Mui E, Deresinski S, Holubar M, Alegria W. Open Forum Infect Dis. 2024
"Electronic Phenotyping" Antimicrobials to Facilitate Outpatient Stewardship for Asymptomatic Bacteriuria and Urinary Tract Infection in Renal Transplant. Zimmet AN, Ha D, Mui E, Smith M, Hawkins M, Alegria W, Holubar M. Open Forum Infect Dis. 2024
Risk factors and outcomes associated with persistent vancomycin resistant Enterococcal Bacteremia. Fox E, Ha D, Bounthavong M, Meng L, Mui E, Holubar M, Deresinski S, Alegria W. BMC Infect Dis. 2022
Shorter durations of antibiotic therapy in organ transplant. Alegria W, Medvedeva N, Holubar M. Curr Opin Organ Transplant. 2022
Characterisation of infections in patients with acute myeloid leukaemia receiving venetoclax and a hypomethylating agent. On S, Rath CG, Lan M, Wu B, Lau KM, Cheung E, Alegria W, Young R, Tan M, Kim C, Phun J, Patel N, Mannis G, Logan AC, Kennedy V, Goodman A, Taplitz RA, Young PA, Wen R, Saunders IM. Br J Haematol. 2022
Early Antibiotic Discontinuation or De-escalation in High-Risk Patients With AML With Febrile Neutropenia and Prolonged Neutropenia. Alegria W, Marini BL, Gregg KS, Bixby DL, Perissinotti A, Nagel J. J Natl Compr Canc Netw. 2022
Effect of rapid methicillin-resistant Staphylococcus aureus nasal polymerase chain reaction screening on vancomycin use in the intensive care unit. Diep C, Meng L, Pourali S, Hitchcock MM, Alegria W, Swayngim R, Ran R, Banaei N, Deresinski S, Holubar M. Am J Health Syst Pharm. 2021 Dec
The Current State of Antifungal Stewardship in Immunocompromised Populations. Alegria W, Patel PK. J Fungi (Basel). 2021
Bacteremia due to Methicillin-Resistant Staphylococcus aureus: An Update on New Therapeutic Approaches. Holubar M, Meng L, Alegria W, Deresinski S. Infect Dis Clin North Am. 2020
Impact of Rapid Antimicrobial Susceptibility Testing in Gram-Negative Rod Bacteremia: a Quasi-experimental Study. Hogan CA, Ebunji B, Watz N, Kapphahn K, Rigdon J, Mui E, Meng L, Alegria W, Holubar M, Deresinski S, Banaei N. J Clin Microbiol. 2020
Antimicrobial Stewardship in Cancer Patients: The Time is Now. Aitken SL, Nagel JL, Abbo L, Alegria W, Barreto JN, Dadwal S, Freifeld AG, Jain R, Pergam SA, Tverdek FP, Seo SK; Antimicrobial Stewardship in Cancer Consortium ASCC. J Natl Compr Canc Netw. 2019 -
Kevin M. Alexander, MD, FACC, FHFSA
Assistant Professor of Medicine (Cardiovascular Medicine)
BioDr. Alexander is an advanced heart failure-trained cardiologist. He is also an Assistant Professor of Cardiovascular Medicine at Stanford University School of Medicine.
Dr. Alexander specializes in the management of advanced heart failure and transplant cases, seeing a wide range of patients. He also has an active research laboratory, studying various forms of heart failure.
Dr. Alexander has expertise in diagnosing and treating transthyretin cardiac amyloidosis, a critical yet underdiagnosed cause of heart failure among African Americans and the elderly. He is conducting extensive research to enhance our understanding of this condition, with grant support from the National Institutes of Health and American Heart Association, among other sources. -
Ash A. Alizadeh, MD/PhD
Moghadam Family Professor
Current Research and Scholarly InterestsMy research is focused on attaining a better understanding of the initiation, maintenance, and progression of tumors, and their response to current therapies toward improving future treatment strategies. In this effort, I employ tools from functional genomics, computational biology, molecular genetics, and mouse models.
Clinically, I specialize in the care of patients with lymphomas, working on translating our findings in prospective cancer clinical trials.
